An estimated 3% of the world’s population have psoriasis, with 6.4 million people affected in Europe. Around one third of psoriasis patients develop psoriatic arthritis, which can lead to irreversible joint damage. Patients also face increased risks of other health issues like cardiovascular diseases and obesity, with higher rates of depression. The HIPPOCRATES research consortium aims to improve early identification and management of PsA. By identifying disease markers, predicting PsA development, and offering personalized treatment options, they hope to prevent irreversible joint damage. The consortium, involving patients in all stages of the project, aims to make a significant impact on psoriasis and PsA management.
Source link
Europe’s Quest for Earlier Diagnosis of Psoriatic Arthritis
